Related resources and publications
Assess T-cell engager in BRGSF-HIS
T-cell engager CD3
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667bc94a3c258196de1731cf_genoway_poster_AACR2024_cd28_webpage.webp)
CD28-targeting therapies
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667be48488917dcbe9803548_sensei_poster_AACR2024_CD28_website_preview.webp)
CD28xVISTA bispecific antibodies in immunotherapy
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667c287be95f147849d772c9_astrazeneca-poster-sitc2023-cd3_preview.webp)
CD3 binding T-cell engagement
hCD3ε immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.
The double-humanized CD3ε/CD28 model was generated from intercrossing hCD3ε and hCD28 mice.
The CD3ε humanized model was developed to express the human epitope of the CD3ε chain, which is recognized by T-cell engagers (clone SP34). The rest of the extracellular domain is murine to preserve the amino acids involved in the interaction with CD3γ and CD3δ. Similarly, the transmembrane domains and the intracellular domains are murine to enable salt bridge interaction, interaction with the CD3ζ, and the signaling into mouse cells.
The humanized CD28 model, developed by Knockin at the mouse CD28 locus, expresses a chimeric CD28 with a human extracellular and murine transmembrane and intracellular domains. hCD28 expression displays a physiological regulation and expression pattern. This double-humanized model enables assessment of both compounds targeting human CD3ε and/or human CD28 in immunocompetent mice.
The hCD3ε/hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human T-cell engager CD3ε(SP-34) and/or the immune checkpoint CD28 in fully immunocompetent mice.
Assess T-cell engager in BRGSF-HIS
T-cell engager CD3
CD28-targeting therapies
CD28xVISTA bispecific antibodies in immunotherapy
CD3 binding T-cell engagement
Let us know how we can help
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate